(NASDAQ: FATE) Fate Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Fate Therapeutics's earnings in 2025 is -$175,879,000.On average, 7 Wall Street analysts forecast FATE's earnings for 2025 to be -$151,315,589, with the lowest FATE earnings forecast at -$176,534,854, and the highest FATE earnings forecast at -$120,364,673. On average, 7 Wall Street analysts forecast FATE's earnings for 2026 to be -$150,822,667, with the lowest FATE earnings forecast at -$204,046,779, and the highest FATE earnings forecast at -$83,682,106.
In 2027, FATE is forecast to generate -$163,925,221 in earnings, with the lowest earnings forecast at -$210,924,760 and the highest earnings forecast at -$116,925,682.